SCHEMBL12502555

SCHEMBL12502555

COc1ccc(Cl)c(-c2nnc3c(C)nc4ccc(F)cc4n23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 20/20 1.00
▸ PDE10A Q9Y233 13/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3326390 0.91 PDE2A (0.84) PDE2APDE10A
SCHEMBL12503054 0.89 PDE2A (1.00) PDE2APDE10A
SCHEMBL14362146 0.87 PDE2A (0.80) PDE2APDE10A
SCHEMBL12502831 0.87 PDE2A (1.00) PDE2APDE10A
SCHEMBL12502817 0.85 PDE2A (1.00) PDE2APDE10A
SCHEMBL3330393 0.85 PDE2A (0.74) PDE2APDE10A
SCHEMBL14361873 0.83 PDE2A (0.83) PDE2APDE10A
SCHEMBL12503036 0.83 PDE2A (1.00) PDE2APDE10A
SCHEMBL14055500 0.83 PDE2A (1.00) PDE2APDE10A
SCHEMBL12502622 0.82 PDE2A (1.00) PDE2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2670754-B1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES BOEHRINGER INGELHEIM INT (DE) 2017-05-24 — — EP claimed
EP-2670754-B1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES BOEHRINGER INGELHEIM INT (DE) 2017-05-24 — — EP disclosed
US-9540379-B2 (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-01-10 — — US disclosed
EP-2670754-A1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES Boehringer Ingelheim International GmbH (DE) 2013-12-11 — — EP disclosed
US-20120302564-A1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES BIOCREA GMBH (DE) 2012-11-29 — — US disclosed
WO-2012104293-A1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302564-A1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES PDE3A, PDE4A, PDE2A PDE2A 3/4885PDE10A 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback